Inhaled iloprost for the control of acute pulmonary hypertension in children: A systematic review

Pediatric Critical Care Medicine

Volumn 13, Issue 4, 2012, Pages 472-480

  Mulligan, Claire ^a   Beghetti, Maurice ^b  

^a OXFORD PHARMAGENESIS LTD   (United Kingdom)

^b WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

Administration, inhalation; Iloprost; Intensive care; Pediatrics; Pulmonary hypertension; Review; Systematic

Indexed keywords

ILOPROST; NITRIC OXIDE;

EMBASE; HEART SURGERY; HUMAN; INTENSIVE CARE UNIT; MEDLINE; PRIORITY JOURNAL; PULMONARY HYPERTENSION; REVIEW; SYSTEMATIC REVIEW;

ACUTE DISEASE; ADMINISTRATION, INHALATION; ADOLESCENT; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; HYPERTENSION, PULMONARY; ILOPROST; MALE; VASODILATOR AGENTS;

EID: 84864284771     PISSN: 15297535     EISSN: 19473893     Source Type: Journal    
DOI: 10.1097/PCC.0b013e31822f192b     Document Type: Review

References (67)

1. McLaughlin VV, Archer SL, Badesch DB, et al: ACCF/AHA 2009 expert consensus document on pulmonary hypertension: A report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association. J Am Coll Cardiol 2009; 53: 1573-1619
2. Galante D, Meola S, Pellico G, et al: Anesthetic management of children with pulmonary arterial hypertension. Paediatr Anaesth 2008; 18: 562-563; author reply 563-564 (Pubitemid 351600200)
3. Hui-Li G: The management of acute pulmonary arterial hypertension. Cardiovasc Ther 2010; 29: 153-175
4. Zamanian RT, Haddad F, Doyle RL, et al: Management strategies for patients with pulmonary hypertension in the intensive care unit. Crit Care Med 2007; 35: 2037-2050 (Pubitemid 47326439)
5. Galie N, Hoeper MM, Humbert M, et al: Guidelines for the diagnosis and treatment of pulmonary hypertension: The Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J 2009; 30: 2493-2537
6. Barst RJ, Stewart D: Conventional and targeted medical therapies. Cardiol Young 2009; 19(Suppl 1): 28-34
7. Haworth SG: The management of pulmonary hypertension in children. Arch Dis Child 2008; 93: 620-625 (Pubitemid 352030089)
8. Rashid A, Ivy D: Severe paediatric pulmonary hypertension: New management strategies. Arch Dis Child 2005; 90: 92-98 (Pubitemid 40063553)
9. Tissot C, Ivy DD, Beghetti M: Medical therapy for pediatric pulmonary arterial hypertension. J Pediatr 2010; 157: 528-532
10. Dunbar Ivy D: Prostacyclin in the intensive care setting. Pediatr Crit Care Med 2010; 11: S41-S45
11. Rimensberger PC, Spahr-Schopfer I, Berner M, et al: Inhaled nitric oxide versus aerosolized iloprost in secondary pulmonary hypertension in children with congenital heart disease: Vasodilator capacity and cellular mechanisms. Circulation 2001; 103: 544-548 (Pubitemid 32116239)
12. Walmrath D, Schneider T, Pilch J, et al: Aerosolised prostacyclin in adult respiratory distress syndrome. Lancet1993; 342: 961-962
13. Olschewski H, Rohde B, Behr J, et al: Pharmacodynamics and pharmacokinetics of inhaled iloprost, aerosolized by three different devices, in severe pulmonary hypertension. Chest 2003; 124: 1294-1304 (Pubitemid 37290038)
14. Olschewski H, Simonneau G, Galie N, et al: Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 2002; 347: 322-329 (Pubitemid 34815354)
15. Rodriguez M, Floristan U, de Lucas Laguna R: A curious but non-serious local side effect of inhaled iloprost: Sudden linear erythematous facial rash. Clin Exp Dermatol 2009; 34: e1014
16. Ivy DD, Doran AK, Smith KJ, et al: Short- and long-term effects of inhaled iloprost therapy in children with pulmonary arterial hypertension. J Am Coll Cardiol 2008; 51: 161-169
17. De Luca D, Zecca E, Piastra M, et al: Iloprost as 'rescue' therapy for pulmonary hypertension of the neonate. Paediatr Anaesth 2007; 17: 394-395 (Pubitemid 46365111)
18. Limsuwan A, Wanitkul S, KhosithsetA, et al: Aerosolized iloprost for postoperative pulmonary hypertensive crisis in children with congenital heart disease. Int J Cardiol 2008; 129: 333-338
19. Opitz CF, Wensel R, Bettmann M, et al: Assessment of the vasodilator response in primary pulmonary hypertension. Comparing prostacyclin and iloprost administered by either infusion or inhalation. Eur Heart J 2003; 24: 356-365 (Pubitemid 36215969)
20. Hoeper MM, Olschewski H, Ghofrani HA, et al: A comparison of the acute hemodynamic effects of inhaled nitric oxide and aerosolized iloprost in primary pulmonary hypertension. German PPH study group. J Am Coll Cardiol 2000; 35: 176-182 (Pubitemid 30061277)
21. Leuchte HH, Schwaiblmair M, Baumgartner RA, et al: Hemodynamic response to sildenafil, nitric oxide, and iloprost in primary pulmonary hypertension. Chest 2004; 125: 580-586 (Pubitemid 38223639)
22. Barst RJ, Gibbs JS, Ghofrani HA, et al: Updated evidence-based treatment algorithm in pulmonary arterial hypertension. J Am Coll Cardiol 2009; 54: S78-S84
23. Hoeper MM, Lee SH, Voswinckel R, et al: Complications of right heart catheterization procedures in patients with pulmonary hypertension in experienced centers. J Am Coll Cardiol 2006; 48: 2546-2552 (Pubitemid 44881214)
24. Jing ZC, Jiang X, Han ZY, et al: Iloprost for pulmonary vasodilator testing in idiopathic pulmonary arterial hypertension. Eur Respir J 2009; 33: 1354-1360
25. Zhang DZ, Zhu XY, Meng J, et al: Acute hemodynamic responses to adenosine and iloprost in patients with congenital heart defects and severe pulmonary arterial hypertension. Int J Cardiol 2011; 147: 433-437
26. Konorza TF, Haude M, Wieneke H, et al: Clinical and pharmacological testing of patients with pulmonary hypertension for treatment decision [in German]. Herz 2005; 30: 286-295 (Pubitemid 40922282)
27. Sitbon O, Humbert M, Jais X, et al: Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation 2005; 111: 3105-3111 (Pubitemid 40847788)
28. Ehlen M, Wiebe B: Iloprost in persistent pulmonary hypertension of the newborn. Cardiol Young 2003; 13: 361-363 (Pubitemid 41630876)
29. Concheiro Guisan A, Sousa Rouco C, Suarez Traba B, et al: Inhaled iloprost: A therapeutic alternative for persistent pulmonary hypertension of the newborn [in Spanish]. An Pediatr (Barc) 2005; 63: 175-176 (Pubitemid 41224610)
30. Sivasli E, Yurdakök M, Karagoöz T, et al: Neonatal pulmoner hipertansiyon tedavisinde inhale iloprost kullanimi. Cocuk Sagligt ve Hastaliklari Dergisi 2005; 48: 142-146 (Pubitemid 40769515)
31. Chotigeat U, Jaratwashirakul S: Inhaled iloprost for severe persistent pulmonary hypertension of the newborn. J Med Assoc Thai 2007; 90: 167-170
32. Eifinger F, Sreeram N, Mehler K, et al: Aerosolized iloprost in the treatment of pulmonary hypertension in extremely preterm infants: A pilot study. Klin Padiatr 2008; 220: 66-69 (Pubitemid 351518681)
33. Ehlen M, Esser R, Kipping T: Inhaled iloprost in pulmonary hypertension and severe respiratory failure in childhood. Monatsschr Kinderheilkd 2003; 151: 539-543 (Pubitemid 36713298)
34. Wittwer T, Pethig K, Struber M, et al: Aerosolized iloprost for severe pulmonary hypertension as a bridge to heart transplantation. Ann Thorac Surg 2001; 71: 1004-1006 (Pubitemid 32210420)
35. Lambert V, Serraf A, Durand P, et al: Aerosolized iloprost therapy in an infant with chronic pulmonary hypertension after a neonatal arterial switch operation [in French]. Arch Pediatr 2001; 8: 1218-1221 (Pubitemid 33077917)
36. Taborosi B, Todt-Pingel I, Kayser G, et al: A rare case of aortic coarctation and ventricular septal defect combined with alveolar capillary dysplasia. Pediatr Cardiol 2007; 28: 319-323 (Pubitemid 46976658)
37. Ozdogan ME, Erer D, Iriz E, et al: Right-to-left shunt through a patent foramen ovale left open in the management of acute right heart failure after heart transplantation. J Heart Lung Transplant 2008; 27: 135-137
38. Loukanov T, Bucsenez D, Springer W, et al: Comparison of inhaled nitric oxide with aerosolized iloprost (Ventavis̊) for treatment of pulmonary hypertension in children after cardiopulmonary bypass surgery. Abstr v521. Clin Res Cardiol 2009; 98: 586
39. Muller M, Scholz S, Kwapisz M, et al: Use of inhaled iloprost in a case of pulmonary hypertension during pediatric congenital heart surgery. Anesthesiology 2003; 99: 743-744 (Pubitemid 37051992)
40. Pac A, Polat TB, Vural K, et al: Successful two-stage correction of ventricular septal defect and patent ductus arteriosus in a patient with fixed pulmonary hypertension. Pediatr Cardiol 2010; 31: 111-113
41. Pac M, Pac FA, Kibar AE, et al: Use of inhaled iloprost therapy in cases of significant pulmonary hypertension during congenital heart surgery. Int J Cardiol 2010; 140: S9
42. Gorenflo M, Bettendorf M, Brockmeier K, et al: Pulmonary vasoreactivity and vasoactive mediators in children with pulmonary hypertension. Z Kardiol 2000; 89: 1000-1008
43. Limsuwan A, Khosithseth A, Wanichkul S, et al: Aerosolized iloprost for pulmonary vasoreactivity testing in children with long-standing pulmonary hypertension related to congenital heart disease. Catheter Cardiovasc Interv 2009; 73: 98-104
44. Limsuwan A, Pakakasama S, Rochanawutanon M, et al: Pulmonary arterial hypertension after childhood cancer therapy and bone marrow transplantation. Cardiology 2006; 105: 188-194
45. Zimmermann R, Kreuder J, Michel-Behnke I, et al: Pulmonary flow reserve in children with idiopathic pulmonary arterial hypertension: Implications for diagnosis and therapy. Eur J Med Res 2006; 11: 208-213
46. Gu H, Li QQ, Zhang C, et al: Inhaled iloprost during acute pulmonary vasodilator testing for preoperative assessment of surgical operability of congenital heart disease with severe pulmonary hypertension [in Chinese]. Zhonghua Wai Ke Za Zhi 2010; 48: 727-730
47. Emmel M, Keuth B, Schickendantz S: Paradoxical increase of pulmonary vascular resistance during testing of inhaled iloprost. Heart 2004; 90: e2
48. Hallioglu O, Dilber E, Celiker A: Comparison of acute hemodynamic effects of aerosolized and intravenous iloprost in secondary pulmonary hypertension in children with congenital heart disease. Am J Cardiol 2003; 92: 1007-1009 (Pubitemid 37214824)
49. Frenckner B, Broome M, Lindstrom M, et al: Platelet-derived growth factor inhibition-A new treatment of pulmonary hypertension in congenital diaphragmatic hernia? J Pediatr Surg 2008; 43: 1928-1931
50. Marx M, Huber WD, Crone J, et al: Interventional stent implantation in a child with patent ductus venosus and pulmonary hypertension. Eur J Pediatr 2001; 160: 501-504
51. Hwang SK, O YC, Kim NS, et al: Use of inhaled iloprost in an infant with bronchopulmonary dysplasia and pulmonary artery hypertension. Korean Circ J 2009; 39: 343-345
52. Bayer HealthCare Pharmaceuticals: Summary of product characteristics. Ventavis 10 microgram/ml. Available at: http://www.ventavis.com/html/pdf/SPC/ SPC-NEU.pdf. Accessed March 25, 2011
53. Gorenflo M, Gu H, Xu Z: Peri-operative pulmonary hypertension in paediatric patients: Current strategies in children with congenital heart disease. Cardiology 2010; 116: 10-17
54. Adatia I, Beghetti M: Early postoperative care of patients with pulmonary hypertension associated with congenital cardiac disease. Cardiol Young 2009; 19: 315-319
55. Loukanov T, Bucsenez D, Springer W, et al: Comparison of inhaled nitric oxide with aerosolized iloprost for treatment of pulmonary hypertension in children after cardiopulmonary bypass surgery. Clin Res Cardiol 2011; 100: 595-602
56. Lopes AA, O'Leary PW: Measurement, interpretation and use of haemodynamic parameters in pulmonary hypertension associated with congenital cardiac disease. Cardiol Young 2009; 19: 431-435
57. Giglia TM, Humpl T: Preoperative pulmonary hemodynamics and assessment of operability: Is there a pulmonary vascular resistance that precludes cardiac operation? Pediatr Crit Care Med 2010; 11: S57-S69
58. Dimopoulos K, PesetA, Gatzoulis MA: Evaluating operability in adults with congenital heart disease and the role of pretreatment with targeted pulmonary arterial hypertension therapy. Int J Cardiol 2008; 129: 163-171
59. Barst RJ, Rubin LJ, Long WA, et al: A comparison of continuous intravenous epoprostenol with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. N Engl J Med 1996; 334: 296-302
60. Yung D, Widlitz AC, Rosenzweig EB, et al: Outcomes in children with idiopathic pulmonary arterial hypertension. Circulation 2004; 110: 660-665 (Pubitemid 39056263)
61. De WetCJ, Affleck DG, Jacobsohn E, et al: Inhaled prostacyclin is safe, effective, and affordable in patients with pulmonary hypertension, right heart dysfunction, and refractory hypoxemia after cardiothoracic surgery. J Thorac Cardiovasc Surg 2004; 127: 1058-1067 (Pubitemid 38451939)
62. McLaughlin VV, Benza RL, Rubin LJ, et al: Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: A randomized controlled clinical trial. J Am Coll Cardiol 2010; 55: 1915-1922
63. Takahashi K, Mori Y, Yamamura H, et al: Effect of beraprost sodium on pulmonary vascular resistance in candidates for a Fontan procedure: A preliminary study. Pediatr Int 2003; 45: 671-675 (Pubitemid 38130359)
64. Durongpisitkul K, Laoprasitiporn D, Layangool T, et al: Comparison of the acute pulmonary vasodilating effect of beraprost sodium and nitric oxide in congenital heart disease. Circ J 2005; 69: 61-64 (Pubitemid 40139609)
65. Nakwan N, Wannaro J: Persistent pulmonary hypertension of the newborn successfully treated with beraprost sodium: A retrospective chart review. Neonatology 2011; 99: 32-37
66. Tapson VF, Torres F, Kermeen F, et al: Results of the FREEDOM-C Study: A pivotal study of oral treprostinil used adjunctively with an ERA and/or PDE5-inhibitor for the treatment of PAH. Am J Respir Crit Care Med 2009; 179: A1040
67. Torbicki A, Lang I, Hoeper M, et al: A new drug class for pulmonary arterial hypertension (PAH): Results from a phase II study of ACT 293987, an oral IP receptor agonist. Eur Heart J 2010; 31(Suppl): 22